Aprea Therapeutics, Inc. Common stock
Veridion Score
BETAMEDIUM CONF · 5/6 factorsComposite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is APRE moving today?
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
APRE overview
Related filings and maps
Congress activity in APRE
No receipt-qualified Congressional disclosure is present for APRE in the cached public ledger.
APRE contract awards, year to date.
Public federal awards linked to this ticker.
APRE lobbying filings, year to date.
Registered lobbying filings matched to Aprea Therapeutics, Inc. Common stock.